Eyexora key facts
- Developer of integrated ophthalmology platforms designed to accelerate the development and delivery of eye care therapies and devices.
- Notable investors include ClavystBio.
- Status: Privately Held (backing).
Who backs Eyexora
1- ·Watch Eyexora: the Monday email on marks, rounds and moves
Eyexora funding rounds
No funding rounds for Eyexora are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Eyexora investors
1 investor is on record for Eyexora, including ClavystBio.
About Eyexora
Developer of integrated ophthalmology platforms designed to accelerate the development and delivery of eye care therapies and devices. The company centralizes scientific, clinical, regulatory, and commercial capabilities within a hub-and-spoke structure, advances a diversified pipeline through specialized subsidiaries, and collaborates with global clinician-scientists and research institutes, enabling ophthalmology-focused organizations to reduce development risk, improve operational efficiency, and scale the impact of innovative treatments for patients worldwide.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- eyexora.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Eyexora doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.